ArticleMolecular biology reports2026
Ameliorative effect of MPAF on DSS-induced ulcerative colitis mice.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUlcerative Colitis (UC) is a common chronic inflammatory intestinal disease. The nut protein peptides are not only easily digested and absorbed, but also possess various physiological functions. This study aims to investigate the protective effects of the Macadamia nut-derived peptide Ala-Cys-Asn-Pro-Phe-Gly-Trp (MPAF) against dextran sulfate sodium (DSS)-induced colitis in mice. METHODS AND
resultsC57BL/6 mice were randomly divided into 5 groups (n = 10): the control group (CON), the DSS group, the low-dose MPAF group (MPAF-L, 50 mg/kg), the high-dose MPAF group (MPAF-H, 100 mg/kg), and 5-Aminosalicylic acid (5-ASA, 100 mg/kg) group. Colon, serum and liver tissues were collected to measure histopathology, antioxidant activity, and the expression levels of genes and proteins associated with the nuclear factor kappa B/NOD-like receptor protein 3 (NF-κB/NLRP3) pathway. Compared to the DSS group, the MPAF and 5-ASA groups exhibited alleviated colon atrophy (the colon length increased by 11.70% and DAI scores decreased by 20.73% in MPAF-H group), attenuated histopathological damage, significant increase in goblet cell numbers (P < 0.05 or P < 0.01), and upregulation of tight junction protein zonula occluden-1 (ZO-1) and mucoprotein-2 (MUC2) (P < 0.01). MPAF and 5-ASA also effectively enhanced antioxidant levels in UC colons (DSS vs. MPAF, P < 0.01), significantly inhibited the expression levels of key factors in the NF-κB/NLRP3 pathway, and reduced pro-inflammatory factors (DSS vs. MPAF-H, P < 0.01).
conclusionsThese findings indicate that MPAF could alleviate oxidative stress and inflammatory responses in the colon, protect the intestinal barrier, and mitigate pathological damage in UC mice. The underlying mechanism may involve suppression of the NF-κB/NLRP3 inflammatory pathway. These results support the potential of MPAF as a functional food ingredient for UC prevention and treatment.
Indexed as
Identifiers
42334529What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.